Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at StockNews.com
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. Several other research analysts have also recently commented on the company. The Goldman Sachs Group initiated coverage on Summit Therapeutics in […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. Several other research analysts have also recently commented on the company. The Goldman Sachs Group initiated coverage on Summit Therapeutics in […]
